Dulaglutide in Diabetic Patients, Relationship Between Arterial Stiffness, Endothelial Function, Clinical and Laboratory Variables

NCT03824002 on ClinicalTrials.gov · last registry update 2019-01-31

Finished 1 October 2017, after enrolling 92 people. Primary outcome, as filed: Change from Baseline Reactive Hyperemia Index at 3 and 9 months. dulaglutide is approved in the US, but not for diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status: COMPLETED
Phase: P4
Drug: dulaglutide
Trulicity
Sponsor: University of Palermo
Sponsor type: Other
Enrollment: 92
Started: 2017-04-01
Primary completion: 2017-10-01 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from Baseline Reactive Hyperemia Index at 3 and 9 months

Conditions studied

Diabetes Mellitus

Every field above is taken directly from the registry record. See all detected changes across the class, or the dulaglutide page for this molecule’s full trial and approval history.